At a glance
- Originator Scios
- Class Antirheumatics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 14 May 2001 Discontinued-Preclinical for Rheumatoid arthritis in USA (PO)
- 06 Nov 1995 No-Development-Reported for Inflammatory bowel disease in USA (PO)
- 06 Nov 1995 No-Development-Reported for Rheumatoid arthritis in USA (PO)